The Cigna Group — Healthcare Plans. Scored on the same transparent 7-signal model behind the daily rankings.
★
CI
The Cigna Group · Healthcare Plans
FCF$7.7bB+
Rev+11.3%B
D/E0.73C+
P/E12.3xA
PEG0.84B+
73.3Score
$291.80$77.2B
1Y Target$340.50Analyst consensus · 24 analysts
5Y Target$429.87Compound horizon
10Y Target$551.30Long-dated conviction
FCF$7.7bTTM · 03/26B+
FCF $7.7b — strong cash profile, above most peers · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+11.3%FY YoYB
Revenue +11.3% — at or above S&P median · Computed from last two annual revenue figures (FY YoY).
D/E0.73C+
D/E 0.73 — above the Healthcare debt median (≈75th pctile)
P/E12.3xA
P/E 12.3 — cheapest decile in Healthcare (≈10th pctile)
PEG0.84B+
PEG 0.84 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 73.3
Quality0.59
Growth0.85
Value0.78
Why this score
Raising its dividend
Entry · Margin of safety
52-week rangeNear 52-week high
8% off the 12-month high
vs DCF fair value41% belowest. fair value ~$498
Why now
Healthcare Plans · market cap $77.2b. 8% off the 52-week high of $315.47. Revenue growing +11%, comfortably above the S&P median. PEG 0.84 — paying under fair value for the growth rate. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $340.50 (implying +17% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 122% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $77.2b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Net margin 2.3% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $340.50 (24-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $429.87 at ~8% CAGR — dividend + buyback compounding. 10 yr $551.30 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · CI
$
%
%
Shares to buy
6
Position size
$1,751
3.5% of portfolio
Stop price
$218.85
25% below $291.80
$ at risk if stopped
$437.70
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
The Cigna Group (CI): score, valuation & FAQ
The Cigna Group (CI) is a Healthcare Plans company that scores 73.3 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A), FCF (B+) and PEG (B+). On valuation, CI sits about 41% below our discounted-cash-flow fair value (a margin of safety).
Is CI a good stock to buy?
Bull Rankings scores CI 73.3 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A), FCF (B+) and PEG (B+). A score is a quantitative screen of The Cigna Group's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CI score 73.3 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). CI earns its highest marks on P/E (A), FCF (B+) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is CI overvalued or undervalued?
Based on $291.80, CI sits about 41% below our discounted-cash-flow fair value (a margin of safety). It trades at a 12.3x× P/E (graded A). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CI?
Net margin 2.3% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.